Stock Price & Analysis

Based on the recent technical analysis and market data, MYO stock shows a clear downward trend with the stock price declining from $4.94 to $2.86 over the past month. The RSI indicator at 25.28 suggests the stock is currently oversold, while the MACD shows a bearish signal with negative values. Given these technical indicators and the recent public offering announcement, selling MYO stock would be advisable at current levels.

Based on the provided data and market analysis, here is the price prediction for MYO stock in 2025:

Technical Analysis

Price Target Analysis According to multiple analyst forecasts and technical indicators, MYO stock is expected to reach:

• Base case: $8.25 (43.7% upside from current $5.74)
• Bull case: $9.00 (56.8% upside)
• Bear case: $7.50 (30.7% upside)

The stock has shown strong momentum with a 50-day SMA at $6.18 and 200-day SMA at $4.60, indicating an overall uptrend. The recent pullback from $6.29 to $5.74 presents a potential buying opportunity as technical indicators suggest the stock is oversold.

Key Growth Drivers

• Expanding medical robotics market and increasing adoption of MyoPro orthotic devices
• Strong revenue growth projected at 5-7% for 2025
• Improving operational efficiency and margin expansion
• Growing Medicare coverage for the company's products

The most likely scenario points to MYO reaching $8.25 by end of 2025, driven by continued market penetration and operational improvements. However, investors should note that this is a small-cap stock with high volatility and risks.

The S1 support level for MYO Stock is $5.27 ,The R1 resistant level for MYO Stock is $6.29.

As of the end of day on 2025-02-25, the price of MYO Stock was $5.08.

The target price for MYO Stock according to analyst rating is 9.00, with the highest price target at 9.00 and the lowest at 9.00. Analysts have a Moderate Buy rating on MYO Stock overall.

The market cap of MYO is $171.8M.

Based on the provided data and technical analysis, MYO appears overvalued at current levels. The stock's RSI-14 reading of 39.82 indicates neutral momentum but trending lower. The stock is trading significantly above its 200-day SMA of $4.60, showing a premium of about 25%. The company's net loss improved from -$10.7M in 2022 to -$8.1M in 2023, but still remains unprofitable with concerning negative ROE of -106%. Recent price action shows weakness with the stock down -2.71% in the last regular session to close at $5.74.

Myomo, Inc. is a wearable medical robotics company that offers improved arm and hand function for those suffering from neurological disorders and upper-limb paralysis. It develops and markets the MyoPro product line. MyoPro is a powered upper-limb orthosis designed to support the arm and restore function to the weakened or paralyzed arms of certain patients suffering from CVA stroke, brachial plexus injury, traumatic brain or spinal cord injury, ALS or other neuromuscular disease or injury. MyoPro senses a patient’s own electromyography (EMG) signals through non-invasive sensors on the arm, and can restore an individual’s ability to perform activities of daily living, including feeding themselves, carrying objects and doing household tasks. It provides devices directly to patients and bill their insurance companies directly. It also sells its products through various other sales channels, including through orthotics and prosthetics providers, the veteran’s administration, and others.

Based on the available data and market analysis, here is the price prediction for MYO stock by 2030:

MYO stock is projected to reach $19.00-$20.00 by 2030, representing approximately a 230% increase from the current price of $5.74. This forecast is driven by the growing prosthetics and orthotics market which is expected to expand at a CAGR of 4.4% through 2030.

The key drivers supporting this long-term price target include:

1. Industry Growth: The global prosthetics and orthotics market size was $6.56 billion in 2024 and is projected to grow steadily through 2030, driven by:

• Rising sports injuries and road accidents
• Increasing diabetes-related amputations
• Growing adoption of advanced prosthetic technologies

2. Technological Innovation: MYO continues to advance its myoelectric technology platform, with recent product launches showing strong market acceptance. The company's focus on robotic arms and prosthetics development positions it well in this growing market.

MYO has a total of 101 employees.